This company listing is no longer active
Acerus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Key information
-329.8%
Debt to equity ratio
US$45.82m
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.02m |
| Equity | -US$13.89m |
| Total liabilities | US$61.57m |
| Total assets | US$47.67m |
Recent financial health updates
Recent updates
Auditors Have Doubts About Acerus Pharmaceuticals (TSE:ASP)
Mar 14
Have Insiders Been Buying Acerus Pharmaceuticals Corporation (TSE:ASP) Shares?
Mar 12Acerus Pharmaceuticals' (TSE:ASP) Shareholders Are Down 88% On Their Shares
Jan 22The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares
Nov 30
Financial Position Analysis
Short Term Liabilities: ASP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ASP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ASP has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ASP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ASP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ASP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 45.6% each year